btog.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

Here’s a short read on your journey to #BTOG25… our latest enewsletter designed for trainees just dropped: www.btog.org/trainee-enew... @gwalls89.bsky.social

submitted 17 hours ago • 0 comments

Midweek memories! A throwback to BTOG 2024 as we count down the days to Monday's kick off! #BTOG25 Watch the full video here www.btog.org/23rd-btog-an...

submitted 2 days ago • 0 comments

The 2nd part of the Therapeutics Symposium at #BTOG25 Annual Conference is chaired by @carlesescriu.bsky.social and @tnewsomdavis.bsky.social, covering “Refining Patient Selection”. btog.org/23rd-btog-an...

submitted 10 days ago • 0 comments

Interesting new compound in the KRAS world, BBO-8520 @theaacr.bsky.social - First-In-Class inhibitor of KRAS G12Ci in GTP-Bound (ON)+GDP-Bound (OFF) states - Ph I ONKORAS-101 trial ongoing, BBO-8520+\- pembro @oncoalert.bsky.social @kraskickers.bsky.social #LCSM aacrjournals.org/cancerdiscov...

submitted 11 days ago • 0 comments

The #BTOG25 Annual Conference Therapeutics Symposium part 1 theme is “Making Antibody-Drug Conjugates (‘ADCs’) Great Again,” chaired by Jason Adhikaree and Yvonne Summers. It will cover everything you ever wanted to know about ADCs but were afraid to ask. #LCSM btog.org/23rd-btog-an...

submitted 15 days ago • 0 comments

Delighted that our #BTOG25 Annual Conference keynote speaker is Pasi Jänne, translational thoracic medical oncologist at the Dana Farber Cancer Institute & professor of medicine at Harvard Medical School. Topic: “Novel strategies to targeting drug tolerant persistent state in lung cancer.” #LCSM

submitted 17 days ago • 0 comments

The @iaslc.bsky.social Staging Cards, 9th Edition, are a set of 22 laminate pocket-sized reference cards which are an excellent resource for those involved with the management of thoracic malignancies. my.iaslc.org/s/store#/sto... #LCSM

submitted 22 days ago • 1 comment

On #WorldCancerDay, for over 20 years BTOG has been working towards our vision to contribute to achieving survival rates equal to the best in the world.

submitted 24 days ago • 0 comments

A great day learning, reflecting and catching up with colleagues. Admittedly my brain feels rather full now! Glad it’s the weekend & time to spend with family! Thanks to @btog.bsky.social for putting on a great study day

submitted 28 days ago • 0 comments

And that's a wrap! Thank you to our expert faculty and delegates for making the day educational and engaging. HCP delegates that are BTOG members will be able to access the slides and recordings within a few days.

submitted 28 days ago • 1 comment

Key takeaways from Rachel Powell on immunotherapy toxicities. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Our final speaker of the day is Rachel Powell on immunotherapy toxicities. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Take home message from Fiona Blackhall when it comes to PDL1 negative in immunotherapy. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Fiona Blackhall now brings us an understanding of PDL1 negative in immunotherapy. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

The 4th and final session of the day is on immunotherapy, chaired by John Conibear and featuring @tnewsomdavis.bsky.social, Fiona Blackhall and Rachel Powell. The topics being covered are: PDL1 ≥50%, duration of IO; PDL1 1-49%; PDL1 negative; and immunotherapy toxicities. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

The Therapeutic Strategies panel is being challenged by the delegates, these debates are the greatest value of our live events. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

John Conibear on managing and preventing brain metastases. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Session 3 on Therapeutic Strategies covers KRAS G12C and others, managing and preventing brain metastases, oligomets and bone metastases management. Chaired by Samreen Ahmed and featuring Fiona Blackhall and John Conibear. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Love the energy Lecture theatre completely full 🤗

submitted 28 days ago • 0 comments

Riyaz Shah hands the baton to @drsanjaypopat.bsky.social to cover MET 14 mutation and amplification, HER2 mutations, and NTRK and Other Fusions. Remember, it's a marathon not a sprint. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

The whistle-stop tour of mutations started with ALK, went quickly to ROS and now leaps from from RET to BRAF. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

ALK done ☑️; next ROS1 #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Session two will cover ALK - 1st line and relapsed settings, ROS and RET fusions, BRAF mutations, MET 14 mutation and amplification, HER2 mutations, NTRK and Other Fusions. Chaired by @tnewsomdavis.bsky.social and featuring Riyaz Shah and @drsanjaypopat.bsky.social. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

How should we be managing EGFR exon 20 mutations? @DrSanjayPopat is the final presenter of this session. Get your questions ready for the panel. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

EGFR rare/co-mutations: What to look out for post-osimertinib #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Key takeaways on EGFR common mutations #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Samreen Ahmed now presents on EGFR common mutations and EGFR rare/co-mutations. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

@drsanjaypopat.bsky.social gives us a masterclass in speaking the language of genomics and understanding genomic reports. #therapeuticupdate25 #lcsm

submitted 28 days ago • 1 comment

@drsanjaypopat.bsky.social kicks off @btog.bsky.social Essential Update in therapeutic options for stage 4 NSCLC ✅ all topics covered ✅ stellar speaker line up ✅ full house 👊👊👊

submitted 28 days ago • 1 comment

The opening session will cover molecular testing and ctDNA utility, EGFR common mutations, EGFR rare/co-mutations and EGFR exon 20 mutations. Chaired by Fiona Blackhall and featuring Samreen Ahmed and @drsanjaypopat.bsky.social, the panel will include all faculty. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Welcome to today’s BTOG Essential Update on Therapeutic Strategies for Stage 4. Our esteemed faculty today is @ProfSIAhmed, @fblackhall, @medicine98, @tnewsomdavis, @DrSanjayPopat, @RachLPowell, and @DrRiyazShah. #therapeuticupdate25 #lcsm

submitted 28 days ago • 0 comments

Follow us here and x.com/BTOGORG for regular updates on tomorrow's Essential Update Event on Therapeutic Strategies for Stage 4. #LCSM

submitted 29 days ago • 0 comments

NEW NICE APPROVAL. NICE has recommended durvalumab with etoposide and either carboplatin or cisplatin, as an option for untreated extensive-stage small-cell lung cancer in adults with an ECOG performance status of 0 or 1. Full details here 👉 bit.ly/4g6U6qZ

submitted 38 days ago • 0 comments

We have extended the deadline for applications to the #BTOG25 Annual Conference Scholarship Fund to close Thursday 9th January 2025. If successful, the scholarship would cover your registration fee to the BTOG annual conference. www.btog.org/23rd-btog-an... #LCSM

submitted 57 days ago • 0 comments

Wishing all those who celebrate a Merry Christmas and a Happy New Year. And a gentle reminder that the #BTOG25 scholarship deadline is 31st December!

submitted 67 days ago • 0 comments

It is worth remembering the times when 🇬🇧 had vastly inferior drug access compared to 🇪🇺 and 🇺🇸 Now, with only a couple of exceptions, we have everything BTOG, working with NICE & advocating for patients, is one reason for this @btog.bsky.social

submitted 68 days ago • 0 comments

NEW NICE APPROVAL: NICE has appraised pembrolizumab, within its marketing authorisation, as an option for the adjuvant treatment of non-small-cell lung cancer (NSCLC) with a high risk of recurrence after complete resection and platinum-based chemotherapy in adults. #LCSM #LungCancer More ...

submitted 70 days ago • 1 comment

It was great to be part of the BTOG/MesoUK Essential Update meeting this week Topics included diagnostics, new Rx, CNS roles, legal, pleural Nice to see 2 current PhD students presenting 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Meso Network (Matt) 🧬 PREDICT-Meso (Mark) @btog.bsky.social @mesouk.bsky.social @uofglasgow.bsky.social

submitted 79 days ago • 0 comments

BTOG is delighted to present an on-site professional childcare service at #BTOG25, acknowledging the requirements of our conference delegates who may be accompanied by their young children. Details on the website www.btog.org/23rd-btog-an...

submitted 79 days ago • 0 comments

New Podcast: BTOG does … MET Part 5 of a series looking at mutations in #lungcancer – we already discussed BRAF, KRAS, RET & ROS1. @tnewsomdavis.bsky.social discussed MET with Alastair Greystoke. Search BTOG in your fav podcast app or listen at BTOG website. www.btog.org/btog-podcasts/ #LCSM

submitted 79 days ago • 0 comments

And in-person member attendees will be able to see the recordings and presentations on the website later this week.

submitted 79 days ago • 0 comments

Final panel of the day, the pleural and palliative care session #mesoupdate24 #LCSM #lungcancer #mesothelioma

submitted 81 days ago • 0 comments

Our final speaker today, Helen Jones presents the legal case for compensation for asbestos in talc #mesoupdate24 #LCSM #lungcancer #mesothelioma

submitted 81 days ago • 0 comments

Our next speaker will give a retrospective case notes review: multiple unmet palliative care needs in pleural mesothelioma @donnawakefield.bsky.social #mesoupdate24 #LCSM #lungcancer #mesothelioma

submitted 81 days ago • 0 comments

Kevin Blyth of @uofglasgow.bsky.social will now discuss the best way to manage symptomatic malignant pleural effusions. #mesoupdate24 #LCSM #lungcancer #mesothelioma

submitted 81 days ago • 0 comments